Feb 8, 2021

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas.  He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a...

Feb 8, 2021

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas.  He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a...

Jan 20, 2021

Dr. Charles Keller, Scientific Director, Children's Cancer Therapy Development Institute is working with a diverse team in this non-profit biotech to make all childhood cancers universally survivable.  Filling the preclinical gap, cc-TDI is moving drugs for pediatric brain tumors and muscle cancers into national...

Jan 20, 2021

Dr. Charles Keller, Scientific Director, Children's Cancer Therapy Development Institute is working with a diverse team in this non-profit biotech to make all childhood cancers universally survivable.  Filling the preclinical gap, cc-TDI is moving drugs for pediatric brain tumors and muscle cancers into national...

Jan 6, 2021

Joseph Sardano, Founder and CEO, Sensus Healthcare presents compelling data on the effectiveness of a non-surgical alternative to Mohs surgery for treating skin cancer and keloids.  Using Superficial Radiation Therapy otherwise known as photon radiotherapy, the Sensus SRT system allows for non-invasive treatments...